Daily7d
FDA approves Semaglutide for renal protection among diabetes patients with CKD
Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...
Business Insider20d
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
Yahoo Finance20d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. The trial included 1,407 ...
The American Journal of Managed Care8d
Case Series Shows Possible Link Between Semaglutide, Ophthalmic Complications
Semaglutide and tirzepatide may be linked to ophthalmic complications due to rapid hyperglycemia correction, not drug toxicity. The study involved nine patients, with seven cases of nonarteritic ...